Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Journal of Perinatal Medicine

Official Journal of the World Association of Perinatal Medicine

Editor-in-Chief: Dudenhausen, MD, FRCOG, Joachim W.

Ed. by Bancalari, Eduardo / Chappelle, Joseph / Chervenak, Frank A. / D'Addario , Vincenzo / Genc, Mehmet R. / Greenough, Anne / Grunebaum, Amos / Konje, Justin C. / Kurjak M.D., Asim / Romero, Roberto / Zalud, MD PhD, Ivica

9 Issues per year


IMPACT FACTOR 2017: 1.558
5-year IMPACT FACTOR: 1.653

CiteScore 2017: 1.26

SCImago Journal Rank (SJR) 2017: 0.594
Source Normalized Impact per Paper (SNIP) 2017: 0.684

Online
ISSN
1619-3997
See all formats and pricing
More options …
Volume 42, Issue 2

Issues

Ferrous bisglycinate 25 mg iron is as effective as ferrous sulfate 50 mg iron in the prophylaxis of iron deficiency and anemia during pregnancy in a randomized trial

Nils Milman / Lisbeth Jønsson / Pernille Dyre / Palle Lyngsie Pedersen / Lise Grupe Larsen
Published Online: 2013-10-24 | DOI: https://doi.org/10.1515/jpm-2013-0153

Abstract

Objective: To compare the effects of oral ferrous bisglycinate 25 mg iron/day vs. ferrous sulfate 50 mg iron/day in the prevention of iron deficiency (ID) and iron deficiency anemia (IDA) in pregnant women. Design: Randomized, double-blind, intention-to-treat study. Setting: Antenatal care clinic. Sample: 80 healthy ethnic Danish pregnant women.

Methods: Women were allocated to ferrous bisglycinate 25 mg elemental iron (Aminojern®) (n=40) or ferrous sulfate 50 mg elemental iron (n=40) from 15 to 19 weeks of gestation to delivery. Hematological status (hemoglobin, red blood cell indices) and iron status (plasma iron, plasma transferrin, plasma transferrin saturation, plasma ferritin) were measured at 15–19 weeks (baseline), 27–28 weeks and 36–37 weeks of gestation. Main outcome measures: Occurrence of ID (ferritin <15 μg/L) and IDA (ferritin <12 μg/L and hemoglobin <110 g/L).

Results: At inclusion, there were no significant differences between the bisglycinate and sulfate group concerning hematological status and iron status. The frequencies of ID and IDA were low and not significantly different in the two iron groups. The frequency of gastrointestinal complaints was lower in the bisglycinate than in the sulfate group (P=0.001). Newborns weight was slightly higher in the bisglycinate vs. the sulfate group (3601±517 g vs. 3395±426 g, P=0.09).

Conclusions: In the prevention of ID and IDA, ferrous bisglycinate was not inferior to ferrous sulfate. Ferrous bisglycinate in a low dose of 25 mg iron/day appears to be adequate to prevent IDA in more than 95% of Danish women during pregnancy and postpartum.

Keywords: anemia; ferritin; food; hemoglobins; iron; iron-deficiency; newborn; pregnancy; supplement

Key Message: In the prevention of iron deficiency and iron deficiency anemia in pregnant women, low-dose ferrous bisglycinate 25 mg iron/day appears to be as effective as ferrous sulfate 50 mg iron/day, most likely due to the higher bioavailability of bisglycinate iron

References

  • [1]

    Brise H. Influence of meals on iron absorption in oral iron therapy. Acta Med Scand. 1962;171, suppl. 376: 39–45.Google Scholar

  • [2]

    Drachenberg CD, Papadimitriou JC. Placental iron deposits: significance in normal and abnormal pregnancies. Hum Pathol. 1994;25:379–85.PubMedGoogle Scholar

  • [3]

    Lund EK, Wharf SG, Fairweather-Tait SJ, Johnson IT. Oral ferrous sulfate supplements increase the free radical-generating capacity of feces from healthy volunteers. Am J Clin Nutr. 1999;69:250–5.Google Scholar

  • [4]

    Marsál K, Persson P-H, Larsen T, Lilja H, Selbing A, Sultan B. Intrauterine growth curves based on ultrasonically estimated foetal weights. Acta Pædiatr. 1996;85:843–8.Google Scholar

  • [5]

    Milman N. Iron and pregnancy – a delicate balance. Ann Hematol. 2006;85:559–65.Google Scholar

  • [6]

    Milman N. Iron prophylaxis in pregnancy general or individual and in which dose? Ann Hematol. 2006;85:821–8.Google Scholar

  • [7]

    Milman N. Prepartum anaemia: prevention and treatment. Ann Hematol. 2008;87:949–59.Web of ScienceGoogle Scholar

  • [8]

    Milman N. Iron in pregnancy how do we secure an appropriate iron status in mother and child? Ann Nutr Metab. 2011;59:50–4.Web of ScienceGoogle Scholar

  • [9]

    Milman N, Agger OA, Nielsen OJ. Iron supplementation during pregnancy. Effect on iron status markers, serum erythropoietin and human placental lactogen. A placebo controlled study in 207 Danish women. Dan Med Bull. 1991;38:471–6.Google Scholar

  • [10]

    Milman N, Bergholt T, Byg K-E, Eriksen L, Graudal N. Iron status and iron balance during pregnancy. A critical reappraisal of iron supplementation. Acta Obstet Gynecol Scand. 1999;78:749–57.Google Scholar

  • [11]

    Milman N, Bergholt T, Eriksen L, Byg K-E, Graudal N, Pedersen P, et al. Iron prophylaxis during pregnancy how much iron is needed? A randomized dose-response study of 20–80 mg ferrous iron daily in pregnant women. Acta Obstet Gynecol Scand. 2005;84:238–47.Google Scholar

  • [12]

    Milman N, Byg K-E, Graudal N, Agger AO. Reference values for hemoglobin and erythrocyte indices during normal pregnancy in 206 women with and without iron supplementation. Acta Obstet Gynecol Scand. 2000;78:89–98.Google Scholar

  • [13]

    Milman N, Clausen J, Byg K-E. Iron status in 268 Danish women aged 18–30 years. Influence of menstruation, method of contraception, and iron supplementation. Ann Hematol. 1998;76:13–9.Google Scholar

  • [14]

    Milman N, Ibsen KK, Christensen JM. Serum ferritin and iron status in mothers and newborn infants. Acta Obstet Gynecol Scand. 1987;66:205–11.PubMedGoogle Scholar

  • [15]

    Nordic Council of Ministers. Nordic Nutrition Recommendations. Scand J Nutr. 1996;40:161–5.Google Scholar

  • [16]

    Pavord S, Myers B, Robinson S, Allard S, Strong J, Oppenheimer C. UK Guidelines on the management of iron deficiency in pregnancy. Br J Haematol. 2012;156:588–600.Google Scholar

  • [17]

    Pedersen P, Melsen GV, Milman N. Frequencies of the hemochromatosis gene (HFE) variants C282Y, H63D and S65C in 6,020 ethnic Danish men. Ann Hematol. 2008;87:735–40.Web of ScienceGoogle Scholar

  • [18]

    Pineda O. Ashmead HDW. Effectiveness of treatment of iron-deficiency anemia in infants and young children with ferrous bisglycinate chelate. Nutrition. 2001;17;381–4.CrossrefGoogle Scholar

  • [19]

    Rossander-Hultén L, Brune M, Sandström B, Lönnerdal B, Hallberg L. Competitive inhibition of iron absorption by manganese and zinc in humans. Am J Clin Nutr. 1991;54:152–6.Google Scholar

  • [20]

    Skikne B, Baynes RD. Iron absorption. In: Brock JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron metabolism in health and disease. London: Saunders; 1994:51–87.Google Scholar

  • [21]

    Sölvell L. Oral iron therapy. Side effects. In: Hallberg L, Harwerth H-G, Vannotti A, editors. Iron deficiency. Pathogenesis, clinical aspects, therapy. London: Academic Press; 1970:573–83.Google Scholar

  • [22]

    Swedish Society of Obstetrics and Gynecology. Mödrahälsovård, sexuell och reproduktiv hälsa. 2008; rapport nr 59:47–8.Google Scholar

  • [23]

    Szarfarc SC, Cassana LMN, Fujimori E, Guerra-Shinohara EM, Oliveira IMV. Relative effectiveness of iron bis-glycinate chelate (Ferrochel) and ferrous sulphate in the control of iron deficiency in pregnant women. Archivos Latinoamericanos de Nutricion. 2001;51 suppl 1:42–7.Google Scholar

  • [24]

    Tetens I, Bendtsen KM, Hansen M, Ersbøll AK, Milman N. The impact of a meat versus a vegetable-based diet on iron status in women of childbearing age with low iron stores. Eur J Nutr. 2007;46:439–45.PubMedGoogle Scholar

  • [25]

    Thomsen JK, Prien-Larsen JC, Devantier A, Fogh-Andersen N. Low dose iron supplementation does not cover the need for iron during pregnancy. Acta Obstet Gynecol Scand. 1993;72:93–8.Google Scholar

  • [26]

    Worwood M. Laboratory determination of iron status. In: Brock, JH, Halliday JW, Pippard MJ, Powell LW, editors. Iron Metabolism in health and disease. London: WB Saunders; 1994:449–76.Google Scholar

About the article

Corresponding author: Nils Milman, Senior Consultant, Lindevangen 87B, DK-2830 Virum, Denmark, Tel.: +45 20103577, Fax: +45 32719401, E-mail:


Received: 2013-06-25

Accepted: 2013-09-08

Published Online: 2013-10-24

Published in Print: 2014-03-01


Citation Information: Journal of Perinatal Medicine, Volume 42, Issue 2, Pages 197–206, ISSN (Online) 1619-3997, ISSN (Print) 0300-5577, DOI: https://doi.org/10.1515/jpm-2013-0153.

Export Citation

©2014 by Walter de Gruyter Berlin Boston.Get Permission

Citing Articles

Here you can find all Crossref-listed publications in which this article is cited. If you would like to receive automatic email messages as soon as this article is cited in other publications, simply activate the “Citation Alert” on the top of this page.

[1]
Ahmed M. Abbas, Safaa A. Abdelbadee, Ahmed Alanwar, and Sayed Mostafa
The Journal of Maternal-Fetal & Neonatal Medicine, 2018, Page 1
[2]
Rimpy Tandon, Arihant Jain, and Pankaj Malhotra
Indian Journal of Hematology and Blood Transfusion, 2018
[3]
Lisette Krul, Bas H. A. Kremer, Niels B. Lucas Luijckx, and Winfried R. Leeman
Critical Reviews in Food Science and Nutrition, 2017, Volume 57, Number 17, Page 3729
[4]
Shiqian Hu and Margaret P. Rayman
Thyroid, 2017, Volume 27, Number 5, Page 597
[5]
Ghada Abdel Fattah Abdel Moety, Ahmed Mahmoud Ali, Reham Fouad, Wafaa Ramadan, Doaa Shafie Belal, and Hisham Mamdouh Haggag
European Journal of Obstetrics & Gynecology and Reproductive Biology, 2017, Volume 210, Page 242
[6]
Francesca Parisi, Cristiana Berti, Chiara Mandò, Anna Martinelli, Cristina Mazzali, and Irene Cetin
The Journal of Maternal-Fetal & Neonatal Medicine, 2017, Volume 30, Number 15, Page 1787

Comments (0)

Please log in or register to comment.
Log in